6% of investigational vaccine recipients and ≤7.8% of PHiD-CV recipients) (Fig. 2). Post-booster, pain was the most common solicited local symptom for most groups (Fig. 2). Specific grade 3 solicited local symptoms were reported for 0.0–9.6% of investigational vaccine recipients and for 0.0–6.0%
of PHiD-CV recipients (Fig. 2). Irritability was the most common solicited general symptom following primary and booster vaccination (Fig. 3). One or more solicited general symptoms were reported for up to 59.6% of participants post-dose 1, 47.1% post-dose 2 and 50.0% post-booster in the investigational groups, and for up to 51.0% post-dose 1, 54.0% post-dose 2 and 38.0% post-booster in the PHiD-CV group (Fig. 3). Incidences of grade 3 solicited general symptoms ranged from 0.0% to 3.9% post-dose 1 and from 0.0% to 2.0% Dactolisib post-dose 2 in the investigational groups; none were reported for
PHiD-CV, except irritability post-dose 2 (2.0%). Post-booster, grade 3 solicited general symptoms were reported by 0.0–3.9% of investigational vaccine recipients and by 0.0–2.0% of PHiD-CV recipients (Fig. 3). Five large swelling reactions were reported: one occurring post-dose 1 and three post-booster in the PHiD-CV/dPly/PhtD-10 group, and one post-dose 2 in the PHiD-CV group. All large swelling reactions were local reactions around the injection site with a diameter of 53–100 mm and onset on day 0 or 1 after vaccination. All resolved completely within maximum two days. Unsolicited AEs considered vaccine-related were reported for one toddler (injection site fibrosis) following dPly/PhtD-10 primary vaccination, for two toddlers (vomiting and injection click here site fibrosis) after dPly/PhtD-10 booster, for one Sodium butyrate toddler (rhinitis) after PHiD-CV/dPly/PhtD-10 booster and for one toddler (rhinitis, insomnia and cough) after PHiD-CV/dPly/PhtD-30 booster. Grade 3 unsolicited AEs were reported for 11 toddlers after primary vaccination (Table S1) and for one toddler after dPly/PhtD-30 booster vaccination (cystitis). Overall, 23 SAEs were reported in 17 toddlers (five, dPly/PhtD-10; three, dPly/PhtD-30; five, PHiD-CV/dPly/PhtD-10; four, PHiD-CV).
None of the SAEs were fatal or considered by the investigators to be vaccine-related; all resolved without sequelae except one (type 1 diabetes mellitus), which was improving at the time of study end. Pre-dose 1, 61.0–75.6% of toddlers in each group were seropositive for PhtD (antibody concentration ≥391 LU/mL). In the investigational vaccine groups, these percentages increased to at least 97.7% one month post-dose 2 and pre-booster, reaching 100% post-booster. In the PHiD-CV group, 85.0–85.4% of toddlers were seropositive for anti-PhtD antibodies at these post-vaccination timepoints (Table 1). A high baseline seropositivity rate for anti-Ply antibodies (antibody concentrations ≥599 LU/mL) was seen in all groups (75.0–88.6%). Seropositivity rates increased in all investigational groups to at least 97.